Out of these 25 patients, 17 had specific genetic alterations suitable for targeted therapy: eight patients had MDM2 and CDK4 amplified dedifferentiated liposarcomas (one of these patients had high HRD score as well) 1 patient had MDM2 and CDK4 amplified well differentiated liposarcoma and 1 patient had sclerosing rhabdomyosarcoma with MDM2 amplification, 1 patient had parosteal osteosarcoma with MDM2 and CDK4 amplification. The gene discussed is MDM2; the disease is juxtacortical osteosarcoma.